Top

Published in:

01-06-2008 | original article

Outcome of Surgical Treatment of Hilar Cholangiocarcinoma

Authors: Kazuhiro Otani, Kazuo Chijiiwa, Masahiro Kai, Jiro Ohuchida, Motoaki Nagano, Kazuyo Tsuchiya, Kazuhiro Kondo

Published in: Journal of Gastrointestinal Surgery | Issue 6/2008

Abstract

To evaluate surgical results and the effect of adjuvant chemotherapy in cases of hilar cholangiocarcinoma, we retrospectively analyzed 27 consecutive patients who underwent surgical resection (eight bile duct resections, 18 bile duct resections plus hepatectomy, one hepatopancreaticoduodenectomy). There was no operative mortality, and the morbidity was 37%. Curative resection (R0 resection) was achieved in 20 (74%) patients. Overall survival at 3 and 5 years was 44% and 27%, significantly higher than that of 47 patients who did not undergo resection (3.5% and 0% at 3 and 5 years, p < 0.0001). Survival of patients with positive margins (R1/2 resection) was poor; there were no 5-year survivors. However, survival was better than that of patients who did not undergo resection (median survival: 22 vs 9 months, p = 0.0007). Univariate analysis identified lymph node metastasis as a negative prognostic factor (p = 0.043). Median survival of patients who underwent adjuvant chemotherapy was significantly longer than that of patients who did not (42 vs. 22 months, p = 0.0428). Resection should be considered as the first option for hilar cholangiocarcinoma. There appears to be a survival advantage even in patients with cancer-positive margins. Adjuvant chemotherapy may increase long-term survival.

Klatskin G. Adenocarcinoma of the hepatic duct at its bifurcation within the porta hepatis. An unusual tumor with distinctive clinical and pathological features. Am J Med 1965;38:241–256.PubMedCrossRef

Bismuth H, Nakache R, Diamond T. Management strategies in resection for hilar cholangiocarcinoma. Ann Surg 1992;215:31–38.PubMedCrossRef

Hemming AW, Reed AI, Fujita S, Foley DP, Howard RJ. Surgical management of hilar cholangiocarcinoma. Ann Surg 2005;241:693–1699; discussion 699–702.PubMedCrossRef

Pichlmayr R, Weimann A, Klempnauer J, Oldhafer KJ, Maschek H, Tusch G, Ringe B. Surgical treatment in proximal bile duct cancer. A single-center experience. Ann Surg 1996;224:628–638.PubMedCrossRef

Jarnagin WR, Bowne W, Klimstra DS, Ben-Porat L, Roggin K, Cymes K, Fong Y, DeMatteo RP, D’Angelica M, Koea J, Blumgart LH. Papillary phenotype confers improved survival after resection of hilar cholangiocarcinoma. Ann Surg 2005;241:703–712.PubMedCrossRef

Kawasaki S, Imamura H, Kobayashi A, Noike T, Miwa S, Miyagawa S. Results of surgical resection for patients with hilar bile duct cancer: Application of extended hepatectomy after biliary drainage and hemihepatic portal vein embolization. Ann Surg 2003;238:84–92.PubMedCrossRef

Jarnagin WR, Fong Y, DeMatteo RP, Gonen M, Burke EC, Bodniewicz Bs J, Youssef Ba M, Klimstra D, Blumgart LH. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 2001;234:507–517; discussion 517–509.PubMedCrossRef

Witzigmann H, Berr F, Ringel U, Caca K, Uhlmann D, Schoppmeyer K, Tannapfel A, Wittekind C, Mossner J, Hauss J, Wiedmann M. Surgical and palliative management and outcome in 184 patients with hilar cholangiocarcinoma: Palliative photodynamic therapy plus stenting is comparable to r1/r2 resection. Ann Surg 2006;244:230–239.PubMedCrossRef

Nimura Y, Kamiya J, Kondo S, Nagino M, Uesaka K, Oda K, Sano T, Yamamoto H, Hayakawa N. Aggressive preoperative management and extended surgery for hilar cholangiocarcinoma: Nagoya experience. J Hepatobiliary Pancreat Surg 2000;7:155–162.PubMedCrossRef

10.

Makuuchi M, Thai BL, Takayasu K, Takayama T, Kosuge T, Gunven P, Yamazaki S, Hasegawa H, Ozaki H. Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma: A preliminary report. Surgery 1990;107:521–527.PubMed

11.

Capussotti L, Muratore A, Polastri R, Ferrero A, Massucco P. Liver resection for hilar cholangiocarcinoma: In-hospital mortality and longterm survival. J Am Coll Surg 2002;195:641–647.PubMedCrossRef

12.

Kondo S, Hirano S, Ambo Y, Tanaka E, Okushiba S, Morikawa T, Katoh H. Forty consecutive resections of hilar cholangiocarcinoma with no postoperative mortality and no positive ductal margins: Results of a prospective study. Ann Surg 2004;240:95–101.PubMedCrossRef

13.

Chijiiwa K, Nishiyama K, Takashima M, Mizumoto K, Noshiro H, Shimizu S, Yamaguchi K, Tanaka M. Diffuse bile duct carcinoma treated by major hepatectomy and pancreatoduodenectomy with the aid of pre-operative portal vein embolization. Report of two cases. Hepatogastroenterology 1999;46:1634–1638.PubMed

14.

Tsao JI, Nimura Y, Kamiya J, Hayakawa N, Kondo S, Nagino M, Miyachi M, Kanai M, Uesaka K, Oda K, Rossi RL, Braasch JW, Dugan JM. Management of hilar cholangiocarcinoma: Comparison of an American and a Japanese experience. Ann Surg 2000;232:166–174.PubMedCrossRef

15.

Pitt HA, Nakeeb A, Abrams RA, Coleman J, Piantadosi S, Yeo CJ, Lillemore KD, Cameron JL. Perihilar cholangiocarcinoma. Postoperative radiotherapy does not improve survival. Ann Surg 1995;221:788–797.PubMedCrossRef

16.

Bismuth H, Corlette MB. Intrahepatic cholangioenteric anastomosis in carcinoma of the hilus of the liver. Surg Gynecol Obstet 1975;140:170–178.PubMed

17.

Kubota K, Makuuchi M, Kusaka K, Kobayashi T, Miki K, Hasegawa K, Harihara Y, Takayama T. Measurement of liver volume and hepatic functional reserve as a guide to decision-making in resectional surgery for hepatic tumors. Hepatology 1997;26:1176–1181.PubMed

18.

UICC. International Union Against Cancer (UICC) TNM Classification of Malignant Tumors. 6th edition. New York: Wiley-Liss. 2002.

19.

Breslow N. Covariance analysis of censored survival data. Biometrics 1974;30:89–99.PubMedCrossRef

20.

Gerhards MF, van Gulik TM, de Wit LT, Obertop H, Gouma DJ. Evaluation of morbidity and mortality after resection for hilar cholangiocarcinoma—a single center experience. Surgery 2000;127:395–404.PubMedCrossRef

21.

Kosuge T, Yamamoto J, Shimada K, Yamasaki S, Makuuchi M. Improved surgical results for hilar cholangiocarcinoma with procedures including major hepatic resection. Ann Surg 1999;230:663–671.PubMedCrossRef

22.

Launois B, Terblanche J, Lakehal M, Catheline JM, Bardaxoglou E, Landen S, Campion JP, Sutherland F, Meunier B. Proximal bile duct cancer: High resectability rate and 5-year survival. Ann Surg 1999;230:266–275.PubMedCrossRef

23.

Klempnauer J, Ridder GJ, von Wasielewski R, Werner M, Weimann A, Pichlmayr R. Resectional surgery of hilar cholangiocarcinoma: A multivariate analysis of prognostic factors. J Clin Oncol 1997;15:947–954.PubMed

24.

Tabata M, Kawarada Y, Yokoi H, Higashiguchi T, Isaji S. Surgical treatment for hilar cholangiocarcinoma. J Hepatobiliary Pancreat Surg 2000;7:148–154.PubMedCrossRef

25.

Boerma EJ. Research into the results of resection of hilar bile duct cancer. Surgery 1990;108:572–580.PubMed

26.

Su CH, Tsay SH, Wu CC, Shyr YM, King KL, Lee CH, Lui WY, Liu TJ, P’Eng F K. Factors influencing postoperative morbidity, mortality, and survival after resection for hilar cholangiocarcinoma. Ann Surg 1996;223:384–394.PubMedCrossRef

27.

Todoroki T, Kawamoto T, Koike N, Takahashi H, Yoshida S, Kashiwagi H, Takada Y, Otsuka M, Fukao K. Radical resection of hilar bile duct carcinoma and predictors of survival. Br J Surg 2000;87:306–313.PubMedCrossRef

28.

Baton O, Azoulay D, Adam DV, Castaing D. Major hepatectomy for hilar cholangiocarcinoma type 3 and 4: Prognostic factors and longterm outcomes. J Am Coll Surg 2007;204:250–260.PubMedCrossRef

29.

Zervos EE, Pearson H, Durkin AJ, Thometz D, Rosemurgy P, Kelley S, Rosemurgy AS. In-continuity hepatic resection for advanced hilar cholangiocarcinoma. Am J Surg 2004;188:584–588.PubMedCrossRef

30.

Veroux M, Madia C, Fiamingo P, Caglia P, Valastro M, Amodeo C, Veroux P, Gagliano M, Basso S, D’Amico DF. Could a high resectability rate improve the long-term survival of patients with proximal bile duct cancer? J Surg Oncol 2006;93:199–205.PubMedCrossRef

31.

Maeno H, Ono T, Yamanoi A, Nagasue N. Our experiences in surgical treatment for hilar cholangiocarcinoma. Hepatogastroenterology 2007;54:669–673.PubMed

32.

Kitagawa Y, Nagino M, Kamiya J, Uesaka K, Sano T, Yamamoto H, Hayakawa N, Nimura Y. Lymph node metastasis from hilar cholangiocarcinoma: Audit of 110 patients who underwent regional and paraaortic node dissection. Ann Surg 2001;233:385–392.PubMedCrossRef

33.

Hasegawa S, Ikai I, Fujii H, Hatano E, Shimahara Y. Surgical resection of hilar cholangiocarcinoma: Analysis of survival and postoperative complications. World J Surg 2007;31:1256–1263.PubMedCrossRef

34.

Silva MA, Tekin K, Aytekin F, Bramhall SR, Buckels JA, Mirza DF. Surgery for hilar cholangiocarcinoma; a 10 year experience of a tertiary referral centre in the UK. Eur J Surg Oncol 2005;31:533–539.PubMedCrossRef

35.

Gerhards MF, van Gulik TM, Gonzalez Gonzalez D, Rauws EA, Gouma DJ. Results of postoperative radiotherapy for resectable hilar cholangiocarcinoma. World J Surg 2003;27:173–179.PubMed

36.

Heron DE, Stein DE, Eschelman DJ, Topham AK, Waterman FM, Rosato EL, Alden M, Anne PR. Cholangiocarcinoma: The impact of tumor location and treatment strategy on outcome. Am J Clin Oncol 2003;26:422–428.PubMedCrossRef

37.

Todoroki T, Ohara K, Kawamoto T, Koike N, Yoshida S, Kashiwagi H, Otsuka M, Fukao K. Benefits of adjuvant radiotherapy after radical resection of locally advanced main hepatic duct carcinoma. Int J Radiat Oncol Biol Phys 2000;46:581–587.PubMed

38.

Schoenthaler R, Phillips TL, Castro J, Efird JT, Better A, Way LW. Carcinoma of the extrahepatic bile ducts. The University of California at San Francisco experience. Ann Surg 1994;219:267–274.PubMedCrossRef

39.

Figueras J, Llado L, Valls C, Serrano T, Ramos E, Fabregat J, Rafecas A, Torras J, Jaurrieta E. Changing strategies in diagnosis and management of hilar cholangiocarcinoma. Liver Transplant 2000;6:786–794.

40.

Serafini FM, Sachs D, Bloomston M, Carey LC, Karl RC, Murr MM, Rosemurgy AS. Location, not staging, of cholangiocarcinoma determines the role for adjuvant chemoradiation therapy. Am Surg 2001;67:839–843.PubMed

41.

Hughes MA, Frassica DA, Yeo CJ, Riall TS, Lillemoe KD, Cameron JL, Donehower RC, Laheru DA, Hruban RH, Abrams RA. Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct. Int J Radiat Oncol Biol Phys 2007;68:178–182.PubMed

Title: Outcome of Surgical Treatment of Hilar Cholangiocarcinoma
Authors: Kazuhiro Otani
Kazuo Chijiiwa
Masahiro Kai
Jiro Ohuchida
Motoaki Nagano
Kazuyo Tsuchiya
Kazuhiro Kondo
Publication date: 01-06-2008
Publisher: Springer-Verlag
Published in: Journal of Gastrointestinal Surgery / Issue 6/2008
Print ISSN: 1091-255X
Electronic ISSN: 1873-4626
DOI: https://doi.org/10.1007/s11605-007-0453-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Outcome of Surgical Treatment of Hilar Cholangiocarcinoma

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2008

Is Totally Laparoscopic Gastrectomy Less Invasive Than Laparoscopy-assisted Gastrectomy?: Prospective, Multicenter Study

On-table Endoscopy Following Laparoscopic Fundoplication

Adenoma of the Major Duodenal Papilla with Intraductal Extension into the Lower Common Bile Duct

Surrogate Markers of Resectability in Patients Undergoing Exploration of Potentially Resectable Pancreatic Adenocarcinoma

An Antecolic Roux-en Y type Reconstruction Decreased Delayed Gastric Emptying after Pylorus-Preserving Pancreatoduodenectomy

Role of Selective α and β Adrenergic Receptor Mechanisms in Rat Jejunal Longitudinal Muscle Contractility